Breakthrough Cancer Vaccine Research Earns Top Honors at University of La Rioja
Table of Contents
A promising new avenue in the fight against cancer has emerged from the University of La Rioja (UR) in Spain, with researchers achieving meaningful breakthroughs in vaccine growth targeting tumor angiogenesis and metastasis. two doctoral candidates, Tom K. Raju and Srdan Tadic, have been awarded their doctorate degrees for theses focused on innovative vaccine strategies, earning the highest rating – “outstanding with international mention” – from the university.
Why This Research Matters
This research is significant as it explores novel vaccine approaches to combat cancer by targeting the mechanisms that allow tumors to grow and spread – angiogenesis and metastasis. Customary cancer treatments often focus on directly killing cancer cells, but these new vaccines aim to prevent tumor development and progression by disrupting the blood supply and spread of cancerous cells.
Who Was Involved?
The key researchers were doctoral candidates Tom K. Raju and srdan tadic, both of the University of La Rioja. Their work was supervised by Doctor Alfredo martínez, the principal investigator of the CIBIR Angiogenesis unit.The research involved experimental models, indicating pre-clinical testing, and builds upon existing knowledge of tumor biology and immunology.
What Were the Key Findings?
Tom K. Raju developed an oral DNA vaccine targeting a peptide called PAMP, which is involved in tumor blood vessel formation. This vaccine showed a significant immune response and reduced tumor angiogenesis in melanoma models. Srdan Tadic created a messenger RNA (mRNA) vaccine targeting adrenomedullin, a protein driving angiogenesis and tumor growth. This vaccine reduced both lung metastases and skin tumor size without harming healthy tissues.
How Did the Research Progress?
Raju’s research involved an oral DNA vaccine, demonstrating the potential for non-invasive vaccine delivery. Tadic’s work utilized lipid nanoparticles – the same technology used in accomplished COVID-19 vaccines – to deliver the mRNA, ensuring effective uptake by cells. Both studies involved experimental models to assess the vaccines’ efficacy in reducing tumor growth and metastasis. The research expanded understanding of how molecules promoting blood vessel growth also influence the immune system.
what Was the Outcome?
Both raju and Tadic were awarded their doctorate degrees with the highest possible rating – “outstanding with international mention” – from the University of La Rioja. Their findings are considered to have “high added value” and could contribute to the development of more effective and less invasive cancer treatments. While still in the pre-clinical stage, the research represents a significant step forward in cancer immunotherapy.
A New Era in Cancer Immunotherapy?
The findings from both doctoral theses “provide scientific knowledge of high added value that could contribute to the development of more effective and less in
